Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Health2Sync
Deal Size : Undisclosed
Deal Type : Collaboration
Merdury Signs MOU with Health2Sync for StackDose Trial in GLP-1 Medication
Details : In this collaboration, the two parties aim to enhance the clinical evidence supporting the pharmacokinetic profile of semaglutide when delivered by StackDose technology in treating obesity.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 25, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Health2Sync
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undislcosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : BIOKEY
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to develop new drug products by leveraging MerDury’s StackDose platform which has the technology to generate new products with unique fast-release properties when it is administered orally.
Brand Name : Undislcosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
June 06, 2023
Lead Product(s) : Undislcosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : BIOKEY
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Ainos and Merdury will evaluate the feasibility of Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's Veldona (interferon alfa) drug candidate for treatment of oral warts i...
Brand Name : Veldona
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 14, 2023
LOOKING FOR A SUPPLIER?